Generex Biotechnology — Investor Presentation (December 2018)
17 slides from Generex Biotechnology's investor presentation, Dec 4, 2018
Slide 1: Presenting Our New Vision As An Integrated Healthcare Holding Company
Strictly Confidential December 3, 2018 Presenting Our New Vision As An Integrated Healthcare Holding Company 1
Slide 2: Legal Disclaimer
Legal Disclaimer 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Forward - looking statements included in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . These statements relate to future e
Slide 3: Transformation: The Past is Gone, A Transformed Generex is Here
3 TRANSFORMATION The Past is Gone…A Transformed Generex is Here…The Future is Bright The “Old” Generex The “New” Generex • Oral - lyn • Type 1 DM • Poor Utility (10 sprays) • Rapid - Mist • Oral - lyn 2 for Type 2 DM • 2 – 3 Sprays @ Mealtime • Licensing deal for buccal CBD • Antigen Express • No pa
Slide 4: Connecting the Healthcare Industry
4 Connecting the Healthcare Industry • Strategic acquisitions • Synergistic alliances • Commercial development • Revenue - generating licensing agreements • Long - term portfolio value through diversification Generex is Reorganized as a Multi - Disciplined Healthcare Holding Company Building Value f
Slide 5: Generex Presents a Vision for Healthcare
5 Generex Presents a Vision for Healthcare An Integrated Healthcare Holding Company CORPORATE MISSION: To provide physicians, hospitals, and healthcare providers an end - to - end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care pro
Slide 6: The NuGenerex Organizational Structure
The NuGenerex Organizational Structure Combines Revenue Generating Healthcare Management Services and Distribution Organizations with Value Driving , Cutting - edge R&D Companies Publicly - Traded Holding Company GNBT NuGenerex Distribution Solutions NuGenerex Management Services NuGenerex Pharmacy
Slide 7: NuGenerex Distribution Solutions Generates Significant Revenues, Profit, and Value
7 NuGenerex Distribution Solutions Generates Significant Revenues, Profit, and Value for Investors Management Services Organization Administrative & billing, Patient compliance, DME, Labs & Imaging Laboratory Multi - State Network Direct - to patient pharmacy solutions Direct - to - patient marketin
Slide 8: Multiple Avenues For Near And Longer-Term Sustainable Growth
8 Multiple Avenues For Near And Longer - Term Sustainable Growth ▪ Current operations in TX, OK, AR, CO, NM o Portfolio expansion ▪ Specialty drugs ▪ Medical devices, ▪ Orphan drugs NuGenerex Today Optimize existing network Expand physician and provider network Extend into new services / add additio
Slide 9: Powerful Synergies & Add-ons Drive Future Performance
9 Powerful Synergies & Add - ons Drive Future Performance Synergies Drive Value • Increase patient engagement • Relationship management • Rx home - delivery • Low - cost specialty and generic Rx • Consumer marketing & outreach • Patient support & education • Additional business opportunities • New p
Slide 10: Acquisition of Olaregen Therapeutix: Excellagen
THERAPEUTICS 10 Acquisitions of Companies with FDA Approved Products and Great Management Strengthens NuGenerex’s Portfolio • Access to Excellagen ® advanced wound care management platform, FDA - approved for 17 indications including: • Diabetic Foot Ulcers • Venous & Arterial Ulcers • Mohs Surgery
Slide 11: Generex Aims to Acquire Advanced Technologies That Fill Gaps in Specialty Medical Care
THERAPEUTICS 11 Generex Aims to Acquire Advanced Technologies That Fill Gaps in Specialty Medical Care » Regentys is developing a novel Extracellular Matrix Hydrogel product aimed at coating the intestinal layer in order to address a variety of GI - related diseases Clinical Development Pathway • 1
Slide 12: Vaccines, Drug Delivery and Diagnostics Programs
12 • Vaccines built on Ii - Key technology • Focusing on stimulating CD - 4 and CD - 8 T - Cells • Planned Phase II trial with AE37 and Keytruda combination for TNBC • Partnership with Shenzhen BioScien to develop and commercialize AE37 for prostate cancer • $700k up - front license fee • Up to $4 M
Slide 13: Developing Point-Of-Care Diagnostic Products in Infectious Diseases
13 SEPSIS Developing Point - Of - Care Diagnostic Products to Meet Today’s Challenges in Infectious Diseases CE Mark, FDA 510K Advancing Diagnostic Testing for Personalized Medicine • Needs only whole blood specimens taken via finger - stick, venipuncture, or processed serum • No need to transfer bl
Slide 14: Rapid-Mist Buccal Spray Drug Delivery System
14 Rapid - Mist™ Buccal Spray Drug Delivery System Reformulated Oral - Lyn 2 for Type 2 Diabetes Co - development and Technology Licensing Agreement for Cannabinoid Drug Delivery • License for RapidMist ™ drug delivery platform technologies for the buccal delivery of cannabinoids and cannabinoid - d
Slide 15: NuGenerex Immuno-Oncology Capitalizes on the Growth of Cancer Immunotherapy
15 Ii - Key Development Program AE37 + Keytruda in TNBC (Merck partnership) AE37 for Prostate Cancer Licensing deal with Shenzhen Bioscien Neoantigen R&D Program (TBD) Acquisitions: • AI Platform • Neo - Antigen Peptides • Checkpoint Inhibitors Partnerships: • Merck • Shenzhen Bioscien • Mayo Clinic
Slide 16: The New Generex Model is an Integrated Healthcare Holdings Company
16 The “New Generex ” Model is an Integrated Healthcare Holdings Company Built for Long - Term Success THERAPEUTICS DIAGNOSTICS IMMUNO - ONCOLGY OWN REVENUE GENERATING BUSINESSES NEAR - TERM GROWTH OPPORTUNITIES • Expand MSO into SC, LA, TN; impending MSO contract with CO hospital group • Launch DME
Slide 17: NuGenerex Family of Companies
NuGenerex Family of Companies
Generex Biotechnology — Investor Presentation (December 2018) on 6ix